Table 3.
Suspected and non-suspected case characteristics in adult and paediatric population.
| Adults |
Paediatric |
|||||
|---|---|---|---|---|---|---|
| Variables | Non suspected N = 797 |
Suspected N= 90 |
p-value | Non suspected N= 64 |
Suspected N=8 |
p-value |
| Age, mean (SD) | 54.17 (15.28) | 45.73 (12.65) | <0.001 | 12.36(3.77) | 15 (2.33 | 0.058 |
| Sex (female), n (%) | 517 (64.9%) | 57 (63.2%) | 0.77 | 43 (67%) | 5 (62%) | 0.79 |
| Rheumatic diseases, n (%) | 0.24 | 0.93 | ||||
| -Rheumatoid arthritis | 368 (46.2%) | 36 (40%) | - | - | ||
| -Axial spondyloarthritis | 200 (25.1%) | 24 (26.7%) | - | - | ||
| -Psoriatic arthritis | 160 (20.1%) | 22 (24.4%) | 1 (2%) | 0 (0%) | ||
| -Juvenile idiopathic arthritis | 61 (7.7%) | 5 (5.6%) | 54 (84%) | 7 (88%) | ||
| -Autoinflammatory syndromes | 8 (1.0%) | 3 (3.3%) | 9 (14%) | 1 (12%) | ||
| Treatment, n (%) | 0.002 | 0.77 | ||||
| -Abatacept | 42 (5.3%) | 3 (3.3%) | 1 (2%) | 0 (0%) | ||
| -Anakinra | 2 (0.3%) | 3 (3.3%) | 8 (12%) | 0 (0%) | ||
| -Apremilast | 6 (0.8%) | 2 (2.2%) | - | - | ||
| -JAKi | 46 (5.8%) | 8 (8.9%) | 1 (2%) | 0 (0%) | ||
| -Rituximab | 4 (0.5%) | 1 (1.1%) | - | - | ||
| -anti-IL17 | 23 (2.9%) | 4 (4.4%) | - | - | ||
| -anti-IL23 | 16 (2%) | 4 (4.4%) | 1 (2%) | 0 (0%) | ||
| -anti-IL6 | 63 (7.9%) | 2 (2.2%) | 5 (8%) | 0 (0%) | ||
| -anti-TNF | 595 (74.5%) | 63 (70%) | 48 (75%) | 8 (100%) | ||
| Hydroxychloroquine, n (%) | 24 (3.0%) | 4 (4.4%) | 0.47 | 0 (0%) | 0 (0%) | - |
| Methotrexate, n (%) | 202 (25.3%) | 20 (2.2%) | 0.48 | 21 (33%) | 2 (25%) | 0.64 |
| Glucocorticoids, mg, median (IQR) | 5 (2.5, 5) (n=333) | 5 (4,5) (n=37) | 0.089 | 2.5 (2.5, 2.5) | - | - |
| Activity index | ||||||
| -DAS28, median (IQR) (n=374) | 2.94 (2.12, 4) | 3.35 (2.96, 4.8) | 0.007 | - | - | - |
| -BASDAI, median (IQR) (n=204) | 3.35(1.4, 5.2) | 3.7 (1.3, 4.6) | 1.00 | - | - | - |
| -DAPSA, median (IQR) (n=143) | 6.06 (3.12, 11.37) | 5 (2.67, 12) | 0.67 | - | - | - |
| Comorbidities | ||||||
| -Hypertension, n (%) | 228 (28.6%) | 18 (20%) | 0.084 | 1 (2%) | 0 (0%) | 0.72 |
| -Diabetes, n (%) | 84 (10.5%) | 6 (6.7%) | 0.25 | 0 (0%) | 0 (0%) | - |
| -Obesity, n (%) | 88 (11.0%) | 7 (7.8%) | 0.34 | 0 (0%) | 0 (0%) | - |
| -Pulmonary disease, n (%) | 107 (13.4%) | 14 (15.6%) | 0.58 | 2 (3%) | 0 (0%) | 0.61 |
| -Smoking, n (%) | 162 (20.3%) | 23 (25.6%) | 0.25 | 0 (0%) | 0 (0%) | - |
| -Cardiovascular disease, n (%) | 84 (10.5%) | 5 (5.6%) | 0.14 | 0 (0%) | 0 (0%) | - |
| -Neoplasia, n (%) | 19 (2.4%) | 2 (2.2%) | 0.92 | 0 (0%) | 0 (0%) | - |
| Symptoms, n (%) | ||||||
| -Dyspnoea | 14 (1.8%) | 19 (21.1%) | <0.001 | 0 (0%) | 0 (0%) | - |
| -Persistent cough | 31 (3.9%) | 70 (77.8%) | <0.001 | 2 (3%) | 4 (50%) | <0.001 |
| -Fever | 7 (0.9%) | 49 (54.4%) | <0.001 | 0 (0%) | 6 (75%) | <0.001 |
| -Odynophagia | 22 (2.8%) | 28 (31.1%) | <0.001 | 0 (0%) | 3 (38%) | <0.001 |
| -Arthralgia/myalgia | 28 (3.5%) | 38 (42.2%) | <0.001 | 1 (2%) | 1 (12%) | 0.076 |
| -Malaise | 34 (4.3%) | 36 (40.0%) | <0.001 | 0 (0%) | 1 (12%) | 0.004 |
| -Headache | 49 (6.1%) | 39 (43.3%) | <0.001 | 1 (2%) | 1 (12%) | 0.076 |
| -Anosmia | 11 (1.4%) | 16 (17.8%) | <0.001 | 0 (0%) | 0 (0%) | |
| -Dysgeusia | 10 (1.3%) | 11 (12.2%) | <0.001 | 0 (0%) | 0 (0%) | |
| -Diarrhoea | 36 (4.5%) | 20 (22.2%) | <0.001 | 1 (2%) | 1 (12%) | 0.076 |
| Contacts | ||||||
| -N° of cohabitants, median (IQR) | 2 (2, 4) | 3 (2, 4) | <0.001 | 4 (4, 5) | 4 (3.5, 5) | 0.30 |
| -Confirmed COVID cohabitant, n (%) | 4 (0.5%) | 7 (7.8%) | <0.001 | 3 (5%) | 1 (12%) | 0.36 |
| -Cohabitant with symptoms, n (%) | 43 (5.4%) | 52 (57.8%) | <0.001 | 9 (14%) | 7 (88%) | <0.001 |
| -N° of cohabitant with symptoms, median (IQR) | 1 (1, 6) | 2 (1, 3) | <0.001 | 6 (1, 6) | 2.5 (2, 3.5) | 0.34 |
| -Confirmed COVID coworker, n (%) | 54 (6.8%) | 17 (18.9%) | <0.001 | 8 (12%) | 3 (38%) | 0.068 |
| -Coworker with symptoms, n (%) | 73 (9.2%) | 35 (38.9%) | <0.001 | 8 (12%) | 4 (50%) | 0.008 |
JAKi: JAK inhibitors, DAS-28: Disease Activity Score-28, BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, DAPSA: Disease Activity in PSoriatic Arthritis score (DAPSA).